Beam Therapeutics (BEAM) Operating Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Operating Expenses data on file, last reported at $139.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 9.62% year-over-year to $139.0 million in Q1 2026; TTM through Mar 2026 was $795.7 million, a 210.11% increase from a year earlier, with the FY2025 full-year figure at $523.4 million, up 2998.17% from the prior year.
• Operating Expenses for Q1 2026 stood at $139.0 million, down from $516.1 million in the prior quarter.
• Over the last five years, Operating Expenses for BEAM reached as high as $516.1 million in Q4 2025 and fell as low as -$324.0 million in Q4 2023.
• Historically, Operating Expenses has averaged $67.0 million across 5 years, with a median of $107.1 million in 2022.
• Across the five-year window, Operating Expenses plunged 323.86% in 2022 and jumped 7889.81% in 2025, its largest moves.
• Year by year, Operating Expenses stood at -$256.4 million in 2022, then dropped by 26.36% to -$324.0 million in 2023, then jumped by 101.99% to $6.5 million in 2024, then soared by 7889.81% to $516.1 million in 2025, then tumbled by 73.08% to $139.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $139.0 million in Q1 2026, $516.1 million in Q4 2025, and $12.0 million in Q3 2025.